Welcome to our dedicated page for Lexaria Bioscience SEC filings (Ticker: LEXX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Lexaria Bioscience Corp. (LEXX) SEC filings page on Stock Titan brings together the company’s official regulatory disclosures, including registration statements, current reports and other documents filed with the U.S. Securities and Exchange Commission. These filings provide structured insight into Lexaria’s DehydraTECH™ drug delivery platform business, intellectual property licensing model and capital markets activity.
Lexaria’s filings include Form S‑1 and Form S‑3 registration statements, which describe the company’s business, risk factors, financial statements and use of proceeds from securities offerings. Investors can review these documents to understand how Lexaria positions DehydraTECH as a patented oral drug delivery formulation and processing technology and how it organizes its operations around IP licensing and research and development.
Frequent Form 8‑K current reports document material events such as securities purchase agreements, registered direct offerings and concurrent private placements of warrants. Recent 8‑K filings detail offerings of common stock and warrants to institutional investors, the terms of those instruments, engagement agreements with placement agents and the intended use of proceeds for working capital, general corporate purposes and R&D programs.
Through these filings, readers can also track Lexaria’s agreements related to capital raising tools, such as sales agreements and their termination, as well as material transfer or licensing arrangements when they rise to the level of reportable events. Stock Titan enhances access to these documents with AI-powered summaries that highlight key terms, capital structure impacts and business implications, helping users quickly interpret complex legal and financial language.
For investors researching LEXX, this page offers real-time access to Lexaria’s SEC filings, including registration statements, 8‑Ks and related exhibits, along with AI-generated explanations of how each filing fits into the company’s broader DehydraTECH-focused strategy.
Lexaria Bioscience Corp. filed a Form S-1 registering for resale up to 2,760,000 shares of common stock issuable upon exercise of outstanding warrants from the September 2025 Offering and an engagement with H.C. Wainwright & Co. The company is not selling any shares in this offering and will not receive proceeds from any resale by the selling stockholders. If the warrants are exercised for cash, Lexaria would receive approximately $3,828,333.
Common stock outstanding was 22,225,846 shares as of October 9, 2025, and would be 24,985,846 shares assuming exercise of all registered warrants. The prospectus outlines standard methods of sale by selling stockholders and notes Nasdaq listings under “LEXX” and “LEXXW.” Risk factors include potential price pressure from resales and dilution from warrant exercises, and a going‑concern note citing $4.6 million in cash and cash equivalents against $1.5 million in current liabilities as of May 31, 2025.
Lexaria Bioscience Corp. filed a Form D reporting a completed Regulation D offering under Rule 506(b) for total proceeds of $4,000,000. The filing states the entire offering amount was sold and no remaining securities are available. The offering included registered shares combined with unregistered warrants and a 7% sales commission paid, totaling an estimated $280,000.
The issuer lists its principal place of business in Kelowna, British Columbia, and identifies multiple executives and directors at that address. The offering involved 5 investors, was not connected to any business combination, had a minimum outside investment of $0, and used H.C. Wainwright & Co. as the associated broker-dealer. No proceeds were allocated to payments to named officers, directors, or promoters per the filing.
Lexaria Bioscience Corp. entered into a securities purchase agreement with institutional investors, issuing 2,666,667 shares of common stock in a registered direct offering at $1.50 per share and, in a concurrent private placement, 2,666,667 warrants exercisable at $1.37 per share. The transaction, which closed on September 29, 2025, generated approximately $4.0 million in gross proceeds that the company plans to use for working capital and general corporate purposes.
The private placement warrants are immediately exercisable for five years from the effectiveness of a resale registration statement and include a beneficial ownership cap of 4.99%, which holders may increase up to 9.99% with notice. Lexaria agreed to file a resale registration statement for the warrant shares shortly after signing and to keep it effective until the investors no longer hold these securities.
H.C. Wainwright & Co. acted as placement agent, receiving a 7.0% cash fee on gross proceeds and 93,333 warrants with a $1.875 exercise price, plus specified expense reimbursements. The company also agreed to a 60-day restriction on most additional equity issuances and related registration filings, with limited exceptions.
Lexaria reports clinical study signals for its DehydraTECH oral delivery platform showing several enhanced formulations outperformed the oral GLP-1 control Rybelsus® on 12-week body weight control and body-weight improvement, with statistically significant advantages by week 12 for most enhanced arms. Specific arms showed blood sugar changes: DehydraTECH-liraglutide (Group H) -11.540%, and select DehydraTECH-CBD arms Group A 1.09% and Group B -3.76%. Pharmacokinetic results for DehydraTECH-tirzepatide showed fewer adverse events than injected Zepbound®, lower but steadier blood levels that reached parity with Zepbound by study end. The study reached last patient last visit on August 14, 2025, enabling full sample and data analyses toward a late-2025 final report. DehydraTECH is described as a drug-delivery platform combining APIs with long-chain fatty acid-rich triglyceride oils and carriers to improve oral absorption and tolerability.
Lexaria Bioscience Corp. terminated its Capital on Demand™ Sales Agreement with JonesTrading Institutional Services LLC effective September 19, 2025. This agreement had allowed the company to issue and sell, from time to time, up to $5,000,000 of its common stock through or to JonesTrading as sales agent or principal.
By the time of termination, Lexaria had sold only 14,995 shares under the program, generating $38,236 in gross proceeds. With the agreement now ended, the company no longer has this specific at-the-market equity facility available for future common stock sales.